Why Victoza Matters

Why bother adding Victoza to an already lengthy list of treatments for type 2 diabetes? Is marginal improvement in a clinical trial enough to warrant educating physicians and patients about yet another option? Read more

Novo Nordisk New Prefilled Insulin Pen Receives EU Approval

The European Commission has approved Novo Nordisk’s new prefilled insulin pen – FlexTouch for use in the EU. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) – both modern insulins currently delivered in FlexPen.
FlexTouch, the latest prefilled delivery system from Novo Nordisk, offers a new insulin injection experience for users…
Read more

Victoza Found More Effective Than Byetta and Januvia In Treatment of Type 2 Diabetes

New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not.. Read more

Actor Chris Noth Joins Novo Nordisk Diabetes Education Campaign

Actor Chris Noth and Novo Nordisk have teamed up in a national education program, Ask.Screen.Know., to highlight the need for early diabetes screening and detection in light of the continuing escalation of diabetes prevalence. As an ambassador for the program, the award-winning actor currently appearing on CBS’ show “The Good Wife” and known for his roles as Detective Mike Logan on “Law and Order” and… Read more

Novo Nordisk Issues Letter Reminding Healthcare Professionals of Victoza Risks

Novo Nordisk issued a letter reminding healthcare professionals of important safety information about the type 2 diabetes drug Victoza (liraglutide [rDNA origin]). The letter was issued because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza… Read more

Novo Nordisk Campaign Urges Diabetes Patients to Use Prefilled Insulin Pens

Novo Nordisk is partnering with 2011 IZOD IndyCar Series driver Charlie Kimball to launch the educational program, Drive the Switch, encouraging diabetes patients who use insulin and caregivers to pledge to talk to their healthcare professional about options for insulin delivery, like the prefilled insulin pen device… Read more

Levemir Better for Treating Young Children with Type 1 Diabetes Than Human Basal Insulin

New clinical trial data just published in Pediatric Diabetes shows that Levemir (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycemic risk. Children with type 1 diabetes who are aged under six years… Read more

Novo Nordisk’s New Insulin Pen for Children Wins GOOD DESIGN Award

The Chicago Athenaeum Museum of Architecture and Design in cooperation with The European Centre for Architecture, Art, Design and Urban Studies have chosen to award Novo Nordisk a 2010 GOOD DESIGN™ Awardfor the NovoPen Echo, a new insulin pen designed specifically with the needs of children in mind… Read more

Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan’s ruling regarding Novo Nordisk’s US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable… Read more

Subscribe to our Newsletter

Hide me